

For More Information:

Layna L. Mendlinger
info@vtivision.com

For immediate release

NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens Delivers Over 1.00 D Less Myopic Refractive Progression in Landmark 3-Year PROTECT Randomized Controlled Trial^{1,2}

NaturalVue Multifocal 1 Day significantly slows myopia progression by 1.06 D and axial elongation by 0.58 mm at 36 months.^{1,2}

Anaheim, CA – September 30, 2026: Visioneering Technologies, Inc. (VTI) proudly announce the final three-year results of PROTECT, a **prospective, double-masked, multinational randomized controlled trial** evaluating the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens in myopic children. **Ashley Tuan, OD, MS, PhD, Chief Medical Officer of Visioneering Technologies**, will present the compelling findings at the American Academy of Optometry Annual Meeting in Anaheim, California.

Landmark Results Across Key Measures^{1,2}

Over three years, children wearing NaturalVue Multifocal 1 Day demonstrated the following compared with a virtual control group:

- **1.06 D** less myopic refractive progression (95% CI 0.86 to 1.25, $p < 0.001$)
- **0.58 mm** less axial elongation (95% CI -0.66 to -0.49, $p < 0.001$)

The completed three-year PROTECT results deliver robust clinical evidence across both cycloplegic refractive error and axial length, the two key measures of myopia progression.^{3,4}

Pioneering Optical Design, Now Backed by Randomized Controlled Clinical Evidence

With the successful completion of the PROTECT clinical trial, NaturalVue Multifocal 1 Day stands alone as the first and only catenary power curve soft contact lens design^{5,6} to demonstrate >1.00 D less myopic refractive progression over three years.^{1,2}

“The PROTECT clinical trial adds important three-year double-masked, randomized controlled evidence to what we know about NaturalVue Multifocal 1 Day,” said **Ashley Tuan, OD, MS, PhD**. “What is especially meaningful is the breadth of the findings. We see a large refractive treatment effect together with significant slowing of axial elongation to the expected level for emmetropic children of these ages and ethnicities, providing a more complete picture of NaturalVue's performance in children with myopia.”

Every Diopter Matters

How much myopia a child develops over time matters for long-term ocular health. Independent of any single treatment, published research underscores the importance of magnitude. Slowing myopia by 1.00 D is estimated to reduce the likelihood of developing myopic maculopathy by approximately 40%⁷ and the risk of retinal detachment by approximately 23%.⁸

“Every diopter matters, which is why the magnitude of the completed PROTECT clinical trial results is important,” said **Brett O'Connor, OD, FAAO*, Smith Eye Associates, Ponte Vedra, FL**. “NaturalVue Multifocal 1 Day demonstrated

1.06 D less myopic refractive progression versus control at three years, along with a 0.58 mm reduction in axial elongation versus control.^{1,2} For eye care professionals managing pediatric progressive myopia, the amount of progression you can reduce matters for better long-term eye health and quality of life.”

Meaningful Results for Myopic Children

In the PROTECT clinical trial, children wearing NaturalVue Multifocal 1 Day showed eye growth similar to non-myopic children over 36 months:^{1,2}

- **59%** progressed ≤ 0.25 D per year on average, consistent with the threshold commonly used to define non-progressive myopia.⁹
- **55%** had axial growth within the emmetropic benchmark of the study.^{1,2}
- **Across all age groups studied, average axial growth trends stayed within** published emmetropic growth ranges.^{10,11}

Protecting Vision for Tomorrow

The completed PROTECT clinical trial equips eye care professionals with a powerful evidence base to guide the long-term myopia-management decisions they make for children every day.

“Correcting a child's myopia today is only part of the opportunity,” said **Jeff Pruett, Chief Operating Officer of Visioneering Technologies**. “The broader goal is managing how much myopia each child develops over time, to protect their vision for tomorrow. The PROTECT study gives eye care professionals substantial new evidence to guide that choice, with results that are both statistically and clinically significant. It was rigorously designed: large, multinational, double-masked, randomized and controlled, and independently conducted, monitored, and managed. Now more than ever, it's time to prescribe NaturalVue Multifocal 1 Day.”

To download a Fact Sheet summarizing the findings to date, [click here](#).

About PROTECT

PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial; NCT05159765) is a three-year, prospective, multicenter, double-masked, randomized controlled trial conducted in the United States, Canada, Hong Kong, and Singapore. A total of 145 children aged 7 up to 13 years, with cycloplegic spherical equivalent refraction (CSER) of -0.75 D to -5.00 D and astigmatism of ≤ 1.00 DC, were randomized 2:1 to NaturalVue Multifocal 1 Day (NVMF) or single-vision contact lenses (SVCL). As planned, the SVCL group crossed over to NVMF at 24 months, so 36-month NVMF outcomes were compared with modeled control data.[†] Of the children enrolled, 126 completed the 36-month study. Outcomes were adjusted for age, sex, ethnicity, country, study site, and baseline value.^{**}

The three-year PROTECT results provide clinical evidence on both key measures of myopia progression: cycloplegic spherical equivalent (CSER), measured by autorefraction, and axial length, measured by optical biometry (e.g., IOLMaster, Carl Zeiss Meditec).

About Visioneering Technologies

Visioneering Technologies, Inc. is an innovative eye care company focused on redefining vision through advanced optical design. Its flagship product, NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens, features a proprietary extended-depth-of-focus catenary curve lens design intended to support vision correction across myopia, presbyopia, and astigmatism.

This information may describe uses for this product, including myopia progression control, that the FDA has not approved for use in the United States. It is intended for educational purposes only.

*Dr. O'Connor is a paid consultant of Visioneering Technologies, Inc.

Results are from a single randomized trial and may not apply to patients outside the studied population. Individual results may vary. See the full PROTECT study report for study limitations, and the package insert for indications, contraindications, warnings and precautions.

** Values based on per-protocol cohort: baseline ages 7 to <13, baseline refraction -0.75 D to -5.00 D, n = 102 (p < 0.001).

† 36-month control values were derived from several complementary analyses, including SVCL projections (24-month SVCL patient data projected to 36 months) and a DyNaSynth™ Synthetic control matched to the SVCL group's baseline characteristics. The modeled control trajectories showed a high degree of concordance with published virtual control models.

References

1. Data on file. PROTECT 3-Year Results, 2026. Data adjusted for key variables, including age, sex, ethnicity, country, study site, and baseline value. Per-protocol cohort, baseline age 7–<13 years, -0.75 D to -5.00 D, n = 102 (p < 0.001). All data vs. virtual control group. 36-month single-vision contact lens control values were derived from several complementary analyses, including SVCL projections (24-month SVCL patient data projected to 36 months) and a DyNaSynth™ virtual control matched to the SVCL group's baseline characteristics. The modeled control trajectories showed a high degree of concordance with published virtual control models.
2. Tuan KA, Novak S, Chan J, Dillehay SM; PROTECT Study Group. PROTECT Completed 3-Year Study Results: A Catenary-Curve Multifocal Contact Lens Reduces Pediatric Myopia Progression and Mitigates Common Risk Factors. Poster presented at: American Academy of Optometry Annual Meeting; September 30–October 3, 2026; Anaheim, California.
3. Walline JJ, Robboy MW, Hilmantel G, et al. Food and Drug Administration, American Academy of Ophthalmology, American Academy of Optometry, American Association for Pediatric Ophthalmology and Strabismus, American Optometric Association, American Society of Cataract and Refractive Surgery, and Contact Lens Association of Ophthalmologists Co-Sponsored Workshop: Controlling the Progression of Myopia: Contact Lenses and Future Medical Devices. *Eye Contact Lens*. 2018;44(4):205–211. doi:10.1097/ICL.0000000000000511.
4. Wolffsohn JS, Kollbaum PS, Berntsen DA, et al. IMI – Clinical Myopia Control Trials and Instrumentation Report. *Invest Ophthalmol Vis Sci*. 2019;60(3):M132–M160. doi:10.1167/iovs.18-25955.
5. Irving EL, Yakobchuk-Stanger C. Myopia progression control lens reverses induced myopia in chicks. *Ophthalmic Physiol Opt*. 2017;37(5):576–584. doi:10.1111/opo.12400.
6. Patents Awarded – MULTIFOCAL OPTHALMIC LENS WITH INDUCED APERTURE. See <https://vtivision.com/about/patents/> for patent numbers.
7. Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. *Optom Vis Sci*. 2019;96(6):463–465. doi:10.1097/OPX.0000000000001367.
8. Bullimore MA, Ritchey ER, Shah S, et al. The Risks and Benefits of Myopia Control. *Ophthalmology*. 2021;128(11):1561–1579. doi:10.1016/j.ophtha.2021.04.032. 23% number is a derived number. The paper reports that each 1 D of myopia increases retinal detachment incidence by 30%. The 23% reduction is the inverse (1 – 1/1.30).
9. Chen J, Liu S, Zhu Z, et al. Axial length changes in progressive and non-progressive myopic children in China. *Graefes Arch Clin Exp Ophthalmol*. 2023;261(5):1493–1501. doi:10.1007/s00417-022-05901-5.
10. Naduvilath T, He X, Saunders K, et al. Age, gender and regional/ethnic variations in emmetropic axial growth rate. *Ophthalmic Physiol Opt*. 2025;45(6):1485–1495. doi:10.1111/opo.13545.
11. Zadnik K, Mutti DO, Mitchell GL, Jones LA, Burr D, Moeschberger ML. Normal eye growth in emmetropic schoolchildren. *Optom Vis Sci*. 2004;81(11):819–828. doi:10.1097/01.opx.0000145028.53923.67.

VTI-RCT-PR12 r1